Made in China:Results,TAL (+)MGM China (-)Sands China/Kweichow Moutai (=);CR Phoenix

类别:行业研究 机构:德意志银行 研究员:Michael Tong 日期:2017-08-11

In 1Q, TAL delivered revenue of USD322mn, +65% YoY and 6% aboveDBe/consensus. Enrollment increased by 62% YoY vs. +57% in 1QFY17. 1QNon-GAAP opm was 12.3%, 105bps ahead of consensus. Non-GAAP EPSrecorded USD0.43, 13%/9% above DBe/consensus. Management guided 2Qrevenue growth of 58-60% YoY (61-63% YoY in RMB terms), in line withDBe/street estimates. Deferred revenue was USD959mn, +72% YoY. TALannounced to change ordinary share/ADS ratio from 1:2 to 3:1, effective onAugust 16. We expect 2Q opm to decline by 2.6ppts YoY due to thecontinuous capacity expansion and summer promotion. We believe in 2H thiscapacity will have much better utilization rate due to the strong demand.

    Summer promotion students will also flow to full-price class. So revenue couldmaintain 60% above YoY growth in Q3 and Q4, meanwhile margin will haveYoY improvement. For full year FY18, we expect non GAAP operating profitwill increase 57% YoY to USD268mn. (Alvin Jiang – 852 2203 6241).

    Ex-branding fees (US$8m), 2Q property EBITDA fell a sharp 17% qoq (-1% yoy)to US$131m, partly hurt by bad luck. Results were largely in line with DB butmissed consensus. MGM missed out on the initial phase of Macau VIPrecovery in 4Q16-1Q17, but it managed to participate in the 2nd phase of theVIP resurgence with VIP rolling +9% qoq (+3% yoy) in 2Q. Unfortunately, dueto bad luck, this didn't get translated into GGR. Hence, GGR mkt share fellfrom 8.4% in 2Q16 to 6.7% in 2Q17 (7.5% in 1Q17). MGM Cotai propertyremained on track to open by 4Q2017 with no VIP rooms at opening. That said,we believe VIP rooms will be added a few months after opening. We revisedup MGM Macau's 2017F EBITDA by 1% to US$569m. Maintain Hold rating.

    (Karen Tang – 852 2203 6141)

数据推荐

投资评级

更多>>
股票名称最新评级目标价研报
长城汽车 买入 -- 研报
美诺华 持有 -- 研报
口子窖 持有 -- 研报
伊利股份 持有 -- 研报
青岛啤酒 持有 -- 研报
五粮液 持有 -- 研报
恒实科技 持有 -- 研报
安科生物 买入 -- 研报
维尔利 买入 -- 研报
华东医药 中性 -- 研报
深天马A 买入 -- 研报

盈利预测

评级选股>>
股票名称11年EPS12年EPS研报
长城汽车 1.11 1.58 研报
美诺华 0 0 研报
恒实科技 0 0 研报
安科生物 0.33 0.39 研报
维尔利 1.25 0.77 研报
华东医药 0.92 1.10 研报
深天马A 0.21 0.19 研报
志邦家居 0 0 研报
雅本化学 0.48 0.40 研报
普利制药 0 0 研报
保利地产 1.11 1.17 研报

股票关注度

更多>>
股票名称关注度平均评级最新评级
通威股份 32 持有 买入
中信证券 31 持有 买入
贵州茅台 30 持有 持有
隆基股份 30 买入 买入
三一重工 29 持有 买入
伊利股份 29 持有 持有
华泰证券 29 持有 买入
万科A 29 买入 买入
五粮液 29 持有 持有
格力电器 28 持有 持有
泸州老窖 27 持有 持有
中顺洁柔 27 持有 持有
中信证券 26 持有 买入
美的集团 26 持有 持有
上汽集团 25 持有 买入
中国国旅 25 持有 买入
华能国际 24 持有 买入

行业关注度

更多>>
行业名称关注度关注股票数买入评级数
电子信息 560 84 293
汽车制造 521 34 296
金融行业 472 29 211
建筑建材 434 51 205
化工行业 390 59 98
钢铁行业 386 29 174
电子器件 386 54 218
机械行业 345 41 130
生物制药 311 51 152
家电行业 308 12 130
酿酒行业 273 16 110
房地产 272 31 188
电力行业 247 31 78
煤炭行业 244 23 87
服装鞋类 203 20 97
酒店旅游 194 20 63
食品行业 190 23 64